The phase III GOG 240 trial evaluated bevacizumab in women with advanced cervical cancer - Advisory Board member and lead investigator Krishnansu Tewari outlines the results of the final analysis in this podcast. <a title="Bevacizumab in cervical cancer" href= "http://bit.ly/Tewari-GOG-240-trial" target="_blank" rel= "noopener">Find more on Medicine Matters oncology</a> This content was originally published on Medicine Matters oncology (<a href= "https://oncology.medicinematters.com/">https://oncology.medicinematters.com/</a>) on December 12, 2017.

The phase III GOG 240 trial evaluated bevacizumab in women with advanced cervical cancer - Advisory Board member and lead investigator Krishnansu Tewari outlines the results of the final analysis in this podcast. Find more on Medicine Matters oncology This content was originally published on Medicine Matters oncology (https://oncology.medicinematters.com/) on December 12, 2017.

The phase III GOG 240 trial evaluated bevacizumab in women with advanced cervical cancer - Advisory Board member and lead investigator Krishnansu Tewari outlines the results of the final analysis in this podcast. <a title="Bevacizumab in cervical cancer" href="http://bit.ly/Tewari-GOG-240-trial" rel="noopener noreferrer">Find more on Medicine Matters oncology</a> This content was originally published on Medicine Matters oncology (<a href="https://oncology.medicinematters.com/" rel="noopener noreferrer">https://oncology.medicinematters.com/</a>) on December 12, 2017.

Share Bevacizumab in cervical cancer (with Krishnansu Tewari)

Sign up to save your podcasts

Bevacizumab in cervical cancer (with Krishnansu Tewari)

Bevacizumab in cervical cancer (with Krishnansu Tewari)